Elvina Almuradova

Pan-RAS Inhibitor Shows Early, Deep Molecular Responses in PDAC

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:

Pan-RAS inhibitor Daraxonrasib in 2L of pancreatic cancer

ORR KRAS G12X: 36%, RAS mt: 27%

For comparison ORR with nal-IRI-FU/LV in NAPOLI-1: 7.7%.

Pan-RAS Inhibitor Shows Early, Deep Molecular Responses in PDAC

Additional information.